Latest Research Study on Lice Treatment Market
Global Lice Treatment Market reached US$ 0.1 billion in 2022 and is expected to reach US$ 0.2 billion by 2031, growing with a CAGR of 6.3% during the forecast period 2024-2031.
Lice Treatment refers to the medical or over-the-counter remedies used to eliminate lice tiny parasitic insects that infest human hair and scalp. These treatments typically involve the use of medicated shampoos, creams, or lotions designed to kill the lice and their eggs (nits) and prevent reinfestation.
Lice are a common issue, particularly among children, as they spread easily through close contact. Head lice are the most common, although lice can also infest the body and pubic area. The primary symptoms of lice infestations include itching, red bumps on the scalp, and visible nits attached to hair strands.
Lice treatments are available in various forms, such as chemical treatments (containing permethrin or pyrethrin), natural treatments (like tea tree oil), and manual methods (combing the hair with a fine-toothed nit comb). In some cases, prescription medication may be required for more resistant infestations.
With the increasing concern over antibiotic resistance and side effects from harsh chemicals, natural remedies are gaining popularity. Proper treatment and hygiene, along with disinfecting personal items like combs and hats, are crucial to effectively eliminating lice and preventing reinfestation.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/lice-treatment-market
Market Growth Drivers:
Rise in the Prevalence of Lice Infestation
The growing prevalence of lice infestations is a key factor driving market growth during the forecast period. Head lice (Pediculosis capitis) are a widespread health issue caused by the human louse (Pediculus humanus capitis), an ectoparasite that specifically targets the scalp.
For example, a study published by Health Equity in the National Library of Medicine highlights that head lice affect between 28% and 43% of individuals in poor rural communities and urban slums in Brazil, with children being the most vulnerable group, especially in school clusters.
Rise in Product Approvals by Regulatory Authorities
Increase in The Product Launches
Product approvals by regulatory authorities are crucial for the growth of the lice treatment market, as these approvals ensure the efficacy, quality, and proper labeling of treatment products. The increasing number of product approvals from regulatory bodies across different countries is driving the market forward.
For example, in April 2022, Arbor Pharmaceuticals Inc. (a subsidiary of Azurity Pharmaceuticals, Inc.) received patents in both the U.S. and Canada for its innovative hair care technology. This new product, made with all-natural ingredients, is designed to safely dislodge and remove lice and eggs from the hair and scalp, marking a significant advancement in the lice treatment market.
Increase in The Product Launches
Innovation in new products is a key factor driving the lice treatment market during the forecast period. The introduction of improved formulations and faster delivery mechanisms helps reduce complications and enhances the effectiveness of treatments.
For example, on June 21, 2023, Chosen by Dermatology, an India-based company specializing in hair and scalp treatments, launched Child’s Play, a hair serum made with high plant content. This innovative product can be used as a wash-off treatment to effectively address lice and nits, offering a natural solution for lice removal.
Market Segments:
- By Type: Pediculosis Capitis , Pediculosis Corporis, Pediculosis Pubis
- By Medication: OTC Medications , Prescription Medications
- By Distribution Channel: Hospitals and Clinics, Retail Pharmacies, Online Pharmacies
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Key Players:
- Alliance Pharmaceuticals
- Omega Pharma(Perrigo Company)
- Prestige Brands Holdings Inc.
- Johnson & Johnson Private Limited
- Fleming Medical Ltd
- RID Lice(Oystershell Consumer Health, Inc)
- Nisarg Pharma
- ParaPRO Pharmaceuticals
- ICB Pharma
- Marico
Customize Your Scope: https://www.datamintelligence.com/customize/lice-treatment-market
Regional Growth
North America Accounted for Approximately 38.6% of the Market Share
North America is expected to hold approximately 38.6% of the total market share during the forecast period, driven by factors such as the high prevalence of lice infestations among children, continuous product innovation, advanced healthcare infrastructure, and increasing demand for chemical-free products. Additionally, the region’s cutting-edge technologies give it a competitive edge, fueling further growth in the market.
For example, in August 2021, ParaPRO, a specialty pharmaceutical company, announced the launch of Natroba (spinosad) Topical Suspension, 0.9%—the first FDA-approved drug for scabies in over 30 years. This product is the first targeted topical treatment for scabies infestations, suitable for both adults and pediatric patients aged four and older.
Key Development
In October 2022, Alliance Pharmaceuticals partnered with South Florida Family Health and Research Centers to launch a clinical trial on clinicaltrials.gov. The trial aims to evaluate the safety and efficacy of Vamousse Spray ‘n’ Go compared to a 1% Permethrin control shampoo for treating head lice.
In September 2022, the American Academy of Pediatrics updated its guidelines for diagnosing and treating head lice. The new recommendations included new medications for treatment, an algorithm for managing affected patients, and additional clarifications on both diagnosis and treatment.
